Your session is about to expire
← Back to Search
VX-121 Combination Therapy for Cystic Fibrosis
Study Summary
This trialstudies the safety and effectiveness of a drug for people with cystic fibrosis over the long-term.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not pregnant or breastfeeding.I completed or was part of the VX20-121-102 or VX20-121-103 study without permanently stopping the study drug.You had a bad reaction to the study drug in a previous study.
- Group 1: VX-121/TEZ/D-IVA
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How extensive is the current participation in this research program?
"This medical trial requires 850 individuals, meeting the prerequisites, to sign up and take part. Participants have multiple locations from which they can choose; such as Children's Hospital of Colorado in Aurora, Colorado or ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic fibrosis Center in Toledo, Ohio."
Are there any remaining openings to partake in this trial?
"Clinicaltrials.gov reports that this medical investigation, initially posted on November 8th 2022 is still actively enlisting patients. It was most recently modified a few weeks ago on the 28th of November."
Is VX-121/TEZ/D-IVA safe for administering to people?
"VX-121/TEZ/D-IVA has been evaluated and rated a 3 due to its Phase 3 status, with clinical data providing evidence of efficacy and safety."
Share this study with friends
Copy Link
Messenger